Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.2800 (-1.88%) ($6.2600 - $6.5100) on Thu. Apr. 18, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.98% (three month average) | RSI | 26 | Latest Price | $6.2800(-1.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.1% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) OIH(12%) XOP(12%) XBI(10%) EWI(9%) ONLN(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.49% in a week (0% probabilities). UUP(-10%) BNDX(-10%) GLD(-8%) GDX(-8%) GDXJ(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.49% (StdDev 4.98%) | Hourly BBV | 0 () | Intraday Trend | -1.9% | | | |
|
1 - 5 Day Possible Target | $-5.72(-191.08%) | Resistance Level | $6.86 | 5 Day Moving Average | $6.43(-2.33%) | 10 Day Moving Average | $6.56(-4.27%) | 20 Day Moving Average | $6.86(-8.45%) | To recent high | -48.3% | To recent low | 0% | Market Cap | $178m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |